Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

BACKGROUND: Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic therapy. We present a primary analysis of the safety and ant...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Oncol
Main Authors: Migden, Michael R, Khushalani, Nikhil I, Chang, Anne Lynn S, Lewis, Karl D, Schmults, Chrysalyne D, Hernandez-Aya, Leonel, Meier, Friedegund, Schadendorf, Dirk, Guminski, Alexander, Hauschild, Axel, Wong, Deborah J, Daniels, Gregory A, Berking, Carola, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G, Rischin, Danny
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771329/
https://ncbi.nlm.nih.gov/pubmed/31952975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30728-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki